Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
evidence of the efficacy of bevacizumab in patients with HHT.Both cases also show that symptoms and transfusion requirements improve with this therapy, without an appreciable change in arteriovenous malformations.Like Oosting et al., we found no difference in the size of our patient's pulmonary arteriovenous malformations on CT before and after bevacizumab.Their experience demonstrates the long-term safety and tolerability of bevacizumab in such patients.Our patient continues to report symptomatic benefit more than a year after completing therapy, and he has required only one intravenous infusion of iron during this time.His hemoglobin levels have remained stable at 14 to 15 g per deciliter.The cost of our patient's regimen (a total of 30 mg per kilogram over four cycles) would be approximately $12,000 today.The costs of continuing the drug in the long term, especially without a Food and Drug Administration-approved indication, would be prohibitive.Our case shows that intermittent dosing allows for long-term, symptomatic improvement and stability of pulmonary arteriovenous malformations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this patient, RDN resulted in a progressive decrease in blood pressure from 161/107 mmHg at baseline to 127/81 mmHg at 12-month follow-up.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“However, RDN-induced reductions in MSNA18 and beneficial effects of RDN on conditions that are not traditionally thought to be driven by the kidney, including heart failure and arrthymia19, cannot be wholly explained by alterations in body fluid homeostasis.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“ablation of the renal nerves was also associated with a substantial decrease in muscle sympathetic nerve activity (MSNA), from 56 bursts per minute before RDN to 19 bursts per minute at 12 months after the procedure.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“The hypothesis that renal afferents mediate some of the BP effects of RDN in humans was sparked by the finding that whole-body noradrenaline spillover and MSNA were decreased in a single patient 1 year after RDN170.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [170]
Citations
Cites
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Self-citationNeural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Schlaich, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., Hastings, J., Aggarwal, A., & Esler, M. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000103160.35395.9e · Cited by 514
Self-citationNoradrenaline Release and the Pathophysiology of Primary Human Hypertension
Esler, M., Jennings, G., & Lambert, G. (1989) · American Journal of Hypertension · doi:10.1093/ajh/2.3.140s · Cited by 138
Self-citation
Cited by
Items 301–400 of 763
Lincevicius, G. S., Shimoura, C. G., Nishi, E. E., de Oliveira, T. L., Céspedes, J. G., Bergamaschi, C. T., & Campos, R. R. (2017) · Autonomic Neuroscience · doi:10.1016/j.autneu.2017.06.002 · Cited by 18
Regulation of the sympathetic nervous system by the kidney
Larsen, R. N., Thorp, A. A., & Schlaich, M. P. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000437610.65287.db · Cited by 18
“Demonstrating a contribution of afferent renal pathways in the development of hypertension is difficult, but is supported by demonstrated reductions in muscle sympathetic nerve activity (MSNA) and whole-body norepinephrine spillover following renal denervation [46].”
BackgroundSelf-citationResistant Hypertension and Renal Nerve Denervation
Denker, M. G., & Cohen, D. L. (2015) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-11-4-240 · Cited by 17
Looking back and thinking forwards — 15 years of cardiology and cardiovascular research
Kalman, J. M., Lavandero, S., Mahfoud, F., Nahrendorf, M., Yacoub, M. H., & Zhao, D. H. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0261-7 · Cited by 17
Renal denervation for treatment-resistant hypertension
Mafeld, S. C., Vasdev, N., & Haslam, P. J. (2012) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712468040 · Cited by 19
“…Efferent nerves: efferent sympathetic stimulation results in water retention, sodium reabsoprtion (via α1 adrenoceptors), increased renin release (via β1 adrenergic receptors) and reduced renal blood flow secondary to renal vessel vasoconstriction [Schlaich et al. 2009; Doumas et al. 2010].”
BackgroundRenal denervation: tips and tricks to perform a technically successful procedure
Bertog, S. C., Blessing, E., Vaskelyte, L., Hofmann, I., Id, D., & Sievert, H. (2013) · EuroIntervention · doi:10.4244/eijv9sra14 · Cited by 16
Catheter-based renal denervation in the treatment of resistant hypertension
Stouffer, G. A., DiBona, G. F., Patel, A. D., Kaul, P., & Hinderliter, A. L. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.04.027 · Cited by 16
“RD resulted in a decrease in plasma renin activity and an increase in renal plasma flow reflecting the withdrawal of efferent renal sympathetic nerve activity from the kidney [35].”
Backgroundvan Brussel, P. M., Schattenkerk, D. W. E., Dobrowolski, L. C., de Winter, R. J., Reekers, J. A., Verberne, H. J., Vogt, L., & van den Born, B. H. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.025 · Cited by 18
The Acute Cardiorenal Syndrome: Burden and Mechanisms of Disease
Nijst, P., & Müllens, W. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0218-4 · Cited by 17
Sorota, S. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000064 · Cited by 20
Treatment-resistant hypertension: another Cinderella story
Messerli, F. H., & Bangalore, S. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht028 · Cited by 16
SELECTION OF PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION FOR RENAL DENERVATION
Chichkova, T. Y., Mamchur, S. E., Александрович, Х. Е., Романова, М. П., Mamchur, S. E., & Тришкина, Н. Н. (2017) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2017-6-4-80-88 · Cited by 15
Device-based approaches for renal nerve ablation for hypertension and beyond
Thorp, A. A., & Schlaich, M. P. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00193 · Cited by 15
Self-citationVink, E. E., Boer, A., Verloop, W. L., Spiering, W., Voskuil, M., Vonken, E.-J. P. A., Hoogduin, J. M., Leiner, T., Bots, M. L., & Blankestijn, P. J. (2015) · European Radiology · doi:10.1007/s00330-014-3583-1 · Cited by 15
“Bilateral treatment of the arteries was performed using series of 2-min radio frequency (RF) energy deliveries along each artery [12].”
MethodRenal Sympathetic Denervation for the Treatment of Refractory Hypertension
Leong, K. T. G., Walton, A., & Krum, H. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051812-145353 · Cited by 16
“This was associated with reduction of renal sympathetic activity as evidenced from renal norepinephrine spillover measurements, diminished renin release with a parallel increase in renal plasma flow, and progressive and sustained reductions of central sympathetic outflow from microneurography measurements (39).”
BackgroundSelf-citationSaxena, M., Shour, T., Shah, M., Wolff, C. B., Julu, P. O. O., Kapil, V., Collier, D., Ng, F. L., Gupta, A. K., Balawon, A., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009151 · Cited by 16
Percutaneous Renal Sympathetic Denervation: 2013 and Beyond
Froeschl, M. P. V., Hadziomerovic, A., & Ruzicka, M. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.11.003 · Cited by 19
Grassi, G. M., Seravalle, G., Trevano, F. Q., Spaziani, D., Scalise, F., Auguadro, C., Pizzini, P., Tripepi, G. L., D’Arrigo, G., Mallamaci, F., et al. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01220215 · Cited by 15
“Observations in resistant hypertension show that renal denervation may result in a marked reduction in whole-body norepinephrine spillover (7) and into a sustained decrease in MSNAC (8), even though these fi ndings were not replicated in all studies (9,10).”
Chang, S., Chang, S.-H., Yu, C., Wu, C., Lai, L., Chiang, F., Hwang, J., Lin, J., & Tsai, C. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.01.008 · Cited by 16
Renal Denervation: A Potential Novel Treatment for Type 2 Diabetes Mellitus?
Pan, T., Guo, J., & Teng, G. (2015) · Medicine · doi:10.1097/md.0000000000001932 · Cited by 19
Sun, J.-Y., Su, Z., Yang, J., Sun, W. Y., & Kong, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122511 · Cited by 16
Chandra, A. P., Marron, C. D., Puckridge, P., & Spark, J. I. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.11.005 · Cited by 14
Streitparth, F., Gebauer, B., Nickel, P., Reinke, P., Freyhardt, P., Wieners, G., Hamm, B., & Günther, R. W. (2014) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-014-0850-0 · Cited by 15
“vation using catheter-based RF ablation [5–8, 22].”
Lang, D., Nahler, A., Lambert, T., Grund, M., Kammler, J., Kellermair, J., Blessberger, H., Kypta, A., Steinwender, C., & Auer, J. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12844 · Cited by 15
“However, changes in SNS activity after the procedure were only rarely reported and, if so, results were partly inconclusive.(1,47,48) We know that the pathogenesis of resistant HTN is more complex than just increased SNS activity alone.”
ResultBazoukis, G., Korantzopoulos, P. G., & Tsioufis, C. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.043 · Cited by 14
Potential role of endurance training in altering renal sympathetic nerve activity in CKD?
Howden, E. J., Lawley, J. S., Esler, M., & Levine, B. D. (2016) · Autonomic Neuroscience · doi:10.1016/j.autneu.2016.11.002 · Cited by 16
Self-citationHoogerwaard, A. F., Adiyaman, A., de Jong, M. R., Smit, J. J. J., Delnoy, P. P. H. M., Heeg, J., van Hasselt, B. A. A. M., Misier, A. R. R., Rienstra, M., & Elvan, A. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1287-2 · Cited by 16
Premise, Promise, and Potential Limitations of Invasive Devices to Treat Hypertension
Martin, E. A., & Victor, R. G. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0156-z · Cited by 15
Resistant Hypertension: Underlying Causes and Treatment
Sarwar, M. S., Islam, M. S., Baker, S. M. A., & Hasnat, A. (2013) · Drug Research · doi:10.1055/s-0033-1337930 · Cited by 15
Briant, L. J. B., Stalbovskiy, A. O., Nolan, M. F., CHAMPNEYS, A. R., & Pickering, A. E. (2014) · Journal of Neurophysiology · doi:10.1152/jn.00350.2014 · Cited by 14
“This has recently led to trials of novel therapeutic interventions aimed at reducing the sympathetic overactivity, for example, renal nerve denervation (Schlaich et al. 2009) and carotid sinus stimulation (Jordan et al. 2012).”
BackgroundUzuka, H., Matsumoto, Y., Nishimiya, K., Ohyama, K., Suzuki, H., Amamizu, H., Morosawa, S., Hirano, M., Shindo, T., Kikuchi, Y., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309777 · Cited by 14
Resistant hypertension: baroreflex stimulation as a new tool
Menne, J., Jordan, J., Linnenweber-Held, S., & Haller, H. G. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs504 · Cited by 15
“Contrary to a previously published case report [25], we found no change in the three parameters indicating that renal denervation has no significant effect on central sympathetic activity.”
ResultDesign and simulation of novel laparoscopic renal denervation system: a feasibility study
Ye, E., Baik, J., Lee, S., Ryu, S. Y., Yang, S.-C., Choi, E., Song, W. H., Yuk, H. D., Jeong, C. W., & Park, S. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1468037 · Cited by 13
Miroslawska, A., Gjessing, P. F., Solbu, M. D., Norvik, J. V., Fuskevåg, O., Hanssen, T. A., & Steigen, T. K. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.02.027 · Cited by 15
Spike rate of multi-unit muscle sympathetic nerve fibers after catheter-based renal nerve ablation
Tank, J., Heusser, K., Brinkmann, J., Schmidt, B. M. W., Menne, J., Bauersachs, J. K., Haller, H. G., Diedrich, A., & Jordan, J. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.07.012 · Cited by 15
“In one patient treated with catheter-based renal nerve ablation, MSNA had decreased approximately 27% at week six and 66% at month 12 following the intervention.[26] However, subsequent studies showed no or much smaller MSNA changes following catheter-based renal nerve ablation.”
New Therapeutic Approaches to Resistant Hypertension
Schlaich, M. P., Krum, H., & Esler, M. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0119-1 · Cited by 13
“Mechanistically, the recent demonstration of a substantial and progressive reduction in central sympathetic outflow at baseline and at 1 and 12 months of follow-up accompanying the progressive BP reduction [ 47 ] indicates that alterations in afferent fiber signaling may play an important role in the BP effects associ…”
BackgroundSelf-citationHuang, B. S., Scherlag, B. J., Yu, L., Lu, Z., He, B., & Jiang, H. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0812-9 · Cited by 13
“to reduce efferent renal and central sympathetic activity [10], it is likely that patients with pronounced sympathetic overactivity would benefit the most from RDN [69].”
BackgroundKrum, H., Sobotka, P. A., Mahfoud, F., Esler, M., & Schlaich, M. P. (2011) · Cited by 13
Self-citationChronic Kidney Disease As a Potential Indication for Renal Denervation
Sanders, M. F., & Blankestijn, P. J. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00220 · Cited by 13
Renal Nerve Stimulation as Procedural End Point for Renal Sympathetic Denervation
Hoogerwaard, A. F., de Jong, M. R., & Elvan, A. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0821-y · Cited by 13
Hohl, M., Lauder, L., Sevimli, Ö., Tokcan, M., Wagmann, L., Götzinger, F., Schneider, C., Hübner, U., Lehnert, U., Meyer, M. R., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.20756 · Cited by 15
Cardiovascular Manifestations of Autonomic Disorders
Somers, V. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00094-9 · Cited by 12
Sympathetic Denervation for Treatment of Ventricular Arrhythmias
Lakkireddy, D. (2020) · Journal of Atrial Fibrillation · doi:10.4022/jafib.2404 · Cited by 12
Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part I
Safaryan, A. S., & Sargsyan, V. D. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2693 · Cited by 12
Hoch, H., Stegbauer, J., Potthoff, S. A., Hein, L., Quack, I., Rump, L. C., & Vonend, O. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01223.x · Cited by 12
“In patients with resistant hypertension, renal denervation reduced sympathetic nerve activity and blood pressure (Krum et al., 2009; Schlaich et al., 2009a).”
BackgroundUpdate on the Guytonian view of hypertension
Pao, A. C. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000450777.17698.8e · Cited by 16
“Bilateral renal nerve ablation using this approach in humans does induce a marked decrease in renal norepinephrine spillover from both kidneys and a 50% decrease in renin activity [56].”
BackgroundVeitenheimer, B. J., Engeland, W. C., Guzman, P. A., Fink, G. D., & Osborn, J. W. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00413.2012 · Cited by 12
“It remains unclear why organ/region-selective denervation is effective in attenuating hypertension in humans (51, 52) and certain rat models of hypertension (30, 31), but no such effect was observed in water-deprived rats.”
BackgroundArterial Destiffening Starts Early after Renal Artery Denervation
Berūkštis, A., Navickas, R., Neverauskaitė-Piliponienė, G., Ryliškytė, L., Misiūra, J., Vajauskas, D., Misonis, N., & Laucevičius, A. (2019) · International Journal of Hypertension · doi:10.1155/2019/3845690 · Cited by 13
“Muscle sympathetic nerve activity, assessed by microneurography, decreased toward normal levels at 30 days after RDN [34].”
BackgroundDores, H., Almeida, M., Gonçalves, P. D. A., Branco, P. Q., Gaspar, A., Sousa, H., Gomes, Â. C., Andrade, M. J., Carvalho, M. S., Teles, R. C., et al. (2014) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2013.09.008 · Cited by 16
Parati, G., Ochoa, J. E., & Bilo, G. (2013) · Circulation · doi:10.1161/circulationaha.113.003892 · Cited by 12
Impact of renal denervation on cardiac remodeling in resistant hypertension: A meta‐analysis
Xie, L., Li, Y., Luo, S., & Huang, B. (2024) · Clinical Cardiology · doi:10.1002/clc.24222 · Cited by 11
“32 Moreover, studies have shown that besides its role in treating RH, RDN may also be effective in the management of other diseases associated with excessive activation of the sympathetic nervous system, such as congestive heart failure, 33 atrial fibrillation, 34 obstructive sleep apnea syndrome.”
BackgroundA clinician's perspective of the role of renal sympathetic nerves in hypertension
Briasoulis, Α., & Bakris, G. L. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00075 · Cited by 13
“…number of different experimental animal models of hypertension either prevented, delayed the onset, or reduced the magnitude of the hypertension (Bonjour et al., 1969; Hesse and Johns, 1984; KompanowskaJezierska et al., 2001; Yoshimoto et al., 2004; Schlaich et al., 2009; Salman et al., 2010).”
Backgroundde Jong, M. R., Hoogerwaard, A. F., Adiyaman, A., Smit, J. J. J., Misier, A. R. R., Heeg, J., van Hasselt, B. A. A. M., Gelder, I. C. V., Crijns, H. J. G. M., Lozano, I. F., et al. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1214-6 · Cited by 13
Arterial Hypertension—clinical trials update 2023
Götzinger, F., Kunz, M., Lauder, L., Böhm, M., & Mahfoud, F. (2023) · Hypertension Research · doi:10.1038/s41440-023-01359-y · Cited by 13
“thetic nerve activity to lower BP [41, 42].”
Novel Approaches for the Treatment of the Patient with Resistant Hypertension: Renal Nerve Ablation
Gulati, V., & White, W. B. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0334-9 · Cited by 12
“A recent case report of a 59-year-old patient with resistant hypertension further elucidated the mechanisms of hypertension control through renal denervation therapy (RDN) [23].”
Freisinger, W., Schatz, J., Ditting, T., Lampert, A., Heinlein, S., Lale, N., Schmieder, R. E., & Veelken, R. A. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00011.2012 · Cited by 12
Renal arteries denervation with second generation systems: a remedy for resistant hypertension?
Versaci, F., Sciarretta, S., Scappaticci, M., Calcagno, S., Pietro, R. D., Sbandi, F., Giudici, A. D., Prete, A. D., de Angelis, S., & Biondi‐Zoccai, G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa158 · Cited by 13
“In 2009, Schlaich et al.(6) published the results of the first case of denervation by radiofrequency ablation in a patient with five drug-resistant hypertension (RHTN).”
BackgroundКонради, А. О. (2013) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2013-4-52-63 · Cited by 15
Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies
Papademetriou, V., Tsioufis, C. P., Gradman, A. H., & Punzi, H. A. (2011) · International Journal of Hypertension · doi:10.4061/2011/438198 · Cited by 16
Grassi, G. M., Seravalle, G., Brambilla, G., Bombelli, M., Dell’Oro, R., Gronda, E., & Mancia, G. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0312-5 · Cited by 10
“Twenty-six of the 50 patients enrolled in the study belonged to the randomized-controlled Symplicity-2 trial [15], which focused on the evaluation of the blood pressure effects of the intervention, while the other 24 patients were specifically recruited for this study.”
BackgroundAblação da atividade simpática renal com cateter de ponta irrigada: uma opção atraente?
Staico, R., Armaganijan, L., Dietrich, C. D. O., Abizaid, A., Moreira, D. A. R., Lópes, R. D., de Almeida, J. S., & Franco, M. (2013) · Revista Brasileira de Cardiologia Invasiva · doi:10.1590/s2179-83972013000100004 · Cited by 10
Hu, W., Yu, S., Chen, L., Guo, R., & Zhao, Q. (2015) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2015.05.006 · Cited by 10
“Previous studies suggest that RSD can inhibit the activation of sympathetic nerve system [34], which also participates in the development of PAH [7].”
BackgroundSelective endothelin receptor blockade in resistant hypertension: results of the DORADO trial
Grassi, G. M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.535812 · Cited by 10
“It has also been shown that some nonpharmacological interventions, such as those based on a radiofrequency catheter-based ablation of renal nerves and on an implantable carotid baroreceptor stimulator device, may lower or even normalize elevated blood pressure values in drug-resistant hypertension [2,3].”
BackgroundQiu, M. R., Yin, Y., & Shan, Q. (2013) · Trials · doi:10.1186/1745-6215-14-168 · Cited by 10
“Recently, many clinical researchers [3-6] have verified that catheter-based renal sympathetic denervation (RSD) could be safely used to”
BackgroundJancovski, N., Carter, D. A., Connelly, A. A., Stevens, E. S., Bassi, J. K., Menuet, C., & Allen, A. M. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.082073 · Cited by 10
“The involvement of SNA in the pathogenesis of hypertension is highlighted by the efficacy of catheter-based renal sympathetic denervation as a treatment strategy for patients with drug-resistant hypertension (Schlaich et al. 2009; Mahfoud et al. 2013).”
BackgroundThe Effects of Renal Denervation on Renal Hemodynamics and Renal Vasculature in a Porcine Model
Verloop, W. L., Hubens, L. E. G., Spiering, W., Doevendans, P. A., Goldschmeding, R., Bleys, R. L. A. W., & Voskuil, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141609 · Cited by 10
“[5–7].”
Weber, T., Zweiker, R., Watschinger, B., Grüner, P., Koppelstätter, C., Brandt, M. C., Horina, J. H., Brussee, H., Hohenstein, K., Lambert, T., et al. (2012) · Wiener klinische Wochenschrift · doi:10.1007/s00508-012-0257-3 · Cited by 10
Chen, S., Kiuchi, M. G., Yin, Y., Liu, S., Schratter, A., Acou, W., Meyer, C. G., Pürerfellner, H., Chun, K. R. J., & Schmidt, B. (2019) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.13858 · Cited by 10
Update on Renal Sympathetic Denervation for the Treatment of Hypertension
Rao, A., & Krishnan, N. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01753-x · Cited by 10
Renal Denervation for Arrhythmias: Hope or Hype?
Steinberg, J. S., Pokushalov, E. A., & Mittal, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0392-0 · Cited by 10
Sympathetic nervous system and arterial hypertension: new perspectives, new data
Hering, D., & Narkiewicz, K. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0089 · Cited by 16
Thaung, H. P. A., Yao, Y., Bussey, C. T., Hughes, G., Jones, P. P., Bahn, A., Sammut, I. A., & Lamberts, R. R. (2015) · Experimental Physiology · doi:10.1113/ep085021 · Cited by 10
Naduvathumuriyil, T., Held, U., Steigmiller, K., Denegri, A., Cantatore, S., Obeid, S. N., Flammer, A. J., Ruschitzka, F. T., Lüscher, T. F., & Sudano, I. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14005 · Cited by 11
Takamura, M., Murai, H., Okabe, Y., Okuyama, Y., Hamaoka, T., Mukai, Y., Tokuhisa, H., Inoue, O., Takashima, S., Kato, T., et al. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0760-4 · Cited by 11
Differences in the effectiveness and safety of different renal denervation devices
Ogoyama, Y., & Kario, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01801-9 · Cited by 10
“In their study of renal sympathetic-nerve ablation for uncontrolled hypertension, Schlaich et al. reported the inhibitory effects of MSNA [34].”
Renal Artery Denervation for the Treatment of Hypertension: Opening up New Horizons
Uder, M., Schmid, A., Titze, S. I., & Schmieder, R. E. (2011) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0129-7 · Cited by 10
“alteration in afferent signalling with a resetting of central sympathetic outflow [17].”
BackgroundTorres, Y. C., & Katholi, R. E. (2013) · International Journal of Hypertension · doi:10.1155/2013/513214 · Cited by 10
Moreira, N. J. D., dos Santos, F., Moreira, É. D., Farah, D., de Souza, L. E., da Silva, M. B., Moraes-Silva, I. C., Lincevicius, G. S., Caldini, E. T. E. G., & Irigoyen, M. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-78674-8 · Cited by 11
van Brussel, P. M., Lieve, K. V. V., de Winter, R. J., & Wilde, A. A. M. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.01.046 · Cited by 10
Renal Denervation for Resistant Hypertension: Where Do We Stand?
Liang, B., Zhao, Y.-X., & Gu, N. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01094-6 · Cited by 9
Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases
Li, L., Hu, Z. Y., Xiong, Y., & Yao, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.803984 · Cited by 9
Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system
Azzam, O., Matthews, V. B., & Schlaich, M. P. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000767 · Cited by 10
Self-citationNeurogenic Hypertension: Revelations from Genome-Wide Gene Expression Profiling
Marques, F. Z., & Morris, B. J. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0282-7 · Cited by 9
Ditting, T., Freisinger, W., Rodionova, K., Schatz, J., Lale, N., Heinlein, S., Linz, P. R., Ott, C., Schmieder, R. E., Scrogin, K. E., et al. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00189.2015 · Cited by 11
“Therefore, the benefit of afferent renal nerve ablation for the treatment of refractory hypertension remains controversial (31).”
BackgroundCook, R. F., Bussey, C. T., Mellor, K. M., Cragg, P. A., & Lamberts, R. R. (2017) · Experimental Physiology · doi:10.1113/ep086293 · Cited by 9
“This is essential to improve current therapeutic strategies (β-AR blockers) and could also contribute to the understanding of potential new therapeutics, such as β-adrenergic receptor kinase carboxyl-terminus (β-ARKct; Rengo et al. 2011) and renal denervation (Schlaich et al. 2009).”
BackgroundSympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?
Schlaich, M. P., & Grassi, G. M. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833e0e74 · Cited by 9
Self-citationInteraction of Stress and Dietary NaCl Intake in Hypertension: Renal Neural Mechanisms
DiBona, G. F. (2013) · Comprehensive physiology · doi:10.1002/cphy.c130010 · Cited by 10
Biaggioni, I. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.186809 · Cited by 8
Interventional hypertension: a new hope or a new hype? The need to redefine resistant hypertension
Campese, V. M. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328364d3f1 · Cited by 8
Васильевич, И. М., Emelyanov, I. V., Vakhrushev, A. D., Alieva, A. S., Avdonina, N., Yudina, Y., Lebedev, D. S., Михайлов, Е. Н., & Конради, А. О. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4794 · Cited by 8
Device-Based Therapy for Resistant Hypertension: An Up‐to‐Date Review
Jami, O., Tijani, Y., & Ettahir, A. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00539-0 · Cited by 10
Restoring autonomic balance: future therapeutic targets
Sobotka, P. A., Osborn, J. W., & Paton, J. F. R. (2013) · EuroIntervention · doi:10.4244/eijv9sra24 · Cited by 8
Self-citationResearch needs in the area of device-related treatments for hypertension
Jordan, J., Mann, J. F. E., & Luft, F. C. (2013) · Kidney International · doi:10.1038/ki.2013.56 · Cited by 8
Renal Sympathetic Denervation: MDCT Evaluation of the Renal Arteries
Hutchinson, B. D., Keane, D., & Dodd, J. D. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.8560 · Cited by 8
“It has recently been validated in a randomized controlled multicenter trial [7] in which endovascular catheter technology enabled selective radiofrequency energy delivery in the renal artery lumen, ablating the renal nerves located in the renal artery adventitia [8].”
BackgroundSousa, H., Branco, P. Q., Almeida, M., Gonçalves, P. D. A., Gaspar, A., Dores, H., Mesquita, J., Andrade, M. J., Neuparth, N. M. B., Aleixo, A., et al. (2017) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2016.09.019 · Cited by 12
“reduction in median ACR in patients with diabetes, and a numerical decrease in the smaller subgroup of patients without diabetes.”
BackgroundLiu, L. Y., Lin, P., Liao, F., Lin, S.-I., Chiou, W., Wu, Y., & Lee, Y. (2019) · Europe PMC (PubMed Central) · doi:10.6515/acs.201903_35(2).20181231a · Cited by 10
N-type calcium channel and renal injury
Bai, L., Sun, S., Sun, Y., Wang, F., & Nishiyama, A. (2022) · International Urology and Nephrology · doi:10.1007/s11255-022-03183-8 · Cited by 9
“In contrast, renal denervation was verified by demonstrating a 50% decrease in renal norepinephrine spillover which resulted in a long-term reduction in arterial pressure[20].”
BackgroundEffectiveness of renal denervation in the treatment of hypertension: a literature review
Shah, R. T., & Wang, B. (2022) · Clinical Hypertension · doi:10.1186/s40885-022-00194-6 · Cited by 10
“catheter-based renal denervation (RDN) via radiofrequency (RF), ultrasound energy, and alcohol [8].”
BackgroundSuccessful accessory renal artery denervation in a patient with resistant hypertension
Sünbül, M., Ataş, H., Durmuş, E., & Mutlu, B. (2014) · Heart Views · doi:10.4103/1995-705x.132142 · Cited by 8
“[3] Percutaneous catheter based renal denervation has been shown to reduce blood pressure and the sequel of hypertension via interference with both efferent and afferent sympathetic nerves function and potentially further central mechanisms.[5-7] Symplicity HTN 1 is the pilot feasibility trial carried out in patients…”
BackgroundBlood pressure control in resistant hypertension: new therapeutic options
Grassi, G. M., Quarti‐Trevano, F., Brambilla, G., & Seravalle, G. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.138 · Cited by 9
Metadata
- Authors
- Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- University of Oklahoma Health Sciences Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-27
- Volume
- 361
- Issue
- 9
- Pages
- 932-934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994487234
- Cited by
- 772
- References
- 5
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 19 · 2023: 25 · 2022: 22 · 2021: 19 · 2020: 19 · 2019: 27 · 2018: 31 · 2017: 42 · 2016: 42 · 2015: 52 · 2014: 115 · 2013: 136 · 2012: 95
- FWCI
- 42.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- uncontrolled hypertension, bevacizumab, hereditary hemorrhagic telangiectasia, pulmonary arteriovenous malformation, intermittent dosing, long-term drug safety, iron requirements
- MeSH terms
- Humans, Hypertension, Kidney, Male, Middle Aged, Norepinephrine, Renal Artery, Sympathectomy, Catheter Ablation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.